Nidan Laboratories and Healthcare Limited
NNSE:NIDAN12.65
INR
-0.25
(-1.94%)
ISIN
INE0J6L01013
Return %
Stock
S&P 500
1Y
-31.62
14.20
3Y
-60.53
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Nithin Vithalrao Thorve
- Full Time Employees
- 163
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Swapnshilpa, Behind Aarti Apartment Virar West MA India 401303
- IPO Date
- Nov 12, 2021
- Website
- nidanhealthcare.co.in
- Similar Companies
- Business
- Nidan Laboratories & Healthcare Ltd (NIDAN.NS) provides diagnostic services including pathology, radiology, cardiology, and neurology across India. The company offers a comprehensive range of over 6,000 clinical laboratory tests and profiles for disease prediction, early detection, screening, confirmation, monitoring, prenatal screening, hormonal imbalance, nutritional deficiencies, and lifestyle disorders; imaging services such as computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, sonography, X-radiation, ultrasound, 2D echo, and ECG; cardiology procedures; neurology diagnostics; and health and wellness packages with value-added options like home sample collection, house calls, and report access via SMS, email, web portals, or mobile apps. It operates 35 diagnostic centers under the Nidan Diagnostics brand primarily in Greater Mumbai, targeting individual consumers, healthcare providers, and wellness-focused customers. Founded in 2000 and headquartered at Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (West), Palghar 401303, Maharashtra, India, the company functions as the healthcare division of Nidan Group with approximately 163 employees and focuses on affordable, technology-driven diagnostics in the healthcare services sector. In recent developments, Nidan Laboratories held its 25th Annual General Meeting on September 2, 2025, where shareholders adopted the fiscal year 2025 financials, reappointed director Edwin Dabre, and approved certain related-party transactions while rejecting others; the company also issued a SEBI Regulation 74(5) certificate on October 13, 2025, confirming dematerialization compliance for the quarter ended September 30, 2025, and closed its trading window on September 24, 2025, ahead of half-year results. It reported fiscal year 2025 revenue of INR 24.53 crore, net profit of INR 1.98 crore, and a return on capital employed of 6.17%, with debtor days improving to 18.9 from prior levels amid ongoing operations in the competitive diagnostic industry.